高级检索
当前位置: 首页 > 详情页

Ginsenoside Re Preserves Cardiac Function and Ameliorates Left Ventricular Remodeling in a Rat Model of Myocardial Infarction

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Department of Traditional Chinese Medicine, China-Japan Friendship Hospital, Beijing, People’s Republic of China [2]Center for Cardiovascular Diseases, XiYuan Hospital, China Academy of Chinese Medical Science, Beijing, People’s Republic of China
出处:
ISSN:

关键词: ginsenoside Re myocardial infarction cardiac dysfunction left ventricular remodeling AMPK/TGF-beta 1/Smad2/3 pathways FAK/PI3K p110 alpha/Akt pathways

摘要:
Ginsenoside Re, an herbal ingredient from ginseng, has been demonstrated to protect the heart from various cardiovascular diseases. In this study, we investigated the protective effects and mechanisms of ginsenoside Re (Gin-Re) on cardiac function and left ventricular remodeling in a rat model of myocardial infarction (MI). After ligating the left anterior descending coronary artery, Wistar rats were treated with Gin-Re (135 mg/kg) by gavage everyday for 4 weeks. Serological detection showed that Gin-Re significantly inhibited myocardial injury and attenuated oxidative stress in MI rats. Echocardiographic observation showed that Gin-Re significantly improved cardiac function and prevented left ventricular dilatation induced by MI. Pathological observation found that Gin-Re significantly decreased interstitial fibrosis in the left ventricle of MI rats. Compared with the MI group, Gin-Re treatment promoted AMPK alpha phosphorylation, decreased TGF-beta 1 expression, and attenuated Smad2/3 activation. After Gin-Re treatment, the phosphorylation of FAK, PI3K p110 alpha, and Akt was enhanced in MI rats, while PI3K p110 beta showed no difference compared with the MI group. These results indicate that Gin-Re may improve MI-induced cardiac dysfunction and mitigate ventricular remodeling through regulation of the AMPK/TGF-beta 1/Smad2/3 and FAK/PI3K p110 alpha/Akt signaling pathways.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统 4 区 药学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统 4 区 药学
JCR分区:
出版当年[2018]版:
Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Q3 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Q2 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2018版] 出版当年五年平均[2014-2018] 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者单位: [1]Department of Traditional Chinese Medicine, China-Japan Friendship Hospital, Beijing, People’s Republic of China
通讯作者:
通讯机构: [2]Center for Cardiovascular Diseases, XiYuan Hospital, China Academy of Chinese Medical Science, Beijing, People’s Republic of China [*1]Center for Cardiovascular Diseases, XiYuan Hospital, China Academy of Chinese Medical Science, No. 1 Xiyuan Playground, Haidian District, Beijing 100091, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)